GeekWire

AUGUST 23, 2021

Since early July alone, three of those companies went public: drug discovery platform company Absci raised $200 million, vaccine developer Icosavax raised $180 million and nervous system therapeutics company Eliem Therapeutics raised $80 million. It’s an unprecedented trend. billion, according to EndpointsNews.

Biotechnology 127

Biotechnology Company Trends .Net 127

GeekWire

AUGUST 10, 2020

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).

Biotechnology 115

Biotechnology Industry Research .Net 115

GeekWire

MAY 12, 2020

Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue , to nearly $21 million. The Seattle-based company posted a net loss of $31.4

Biotechnology 112

Biotechnology Pharmaceuticals .Net Microsoft 112

GeekWire

FEBRUARY 24, 2021

Seattle-based Adaptive Biotechnologies, which develops technology to sequence the human immune system to diagnose and treat disease, posted revenue of $30.2 The company’s quarterly net loss more than doubled to $44.6 million due higher costs in the areas of sales and marketing, and research and development.

Company 131

Company Biotechnology .Net Research 131

GeekWire

NOVEMBER 9, 2023

Adaptive Biotechnologies CEO Chad Robins speaks at the GeekWire Summit in 2019. He said the businesses are at different stages of maturity, with different capital and development needs. Adaptive’s net loss came in at $50.3 Robins said they’ve been talking for the past 18 months about their two distinct business opportunities.

Biotechnology 105

Biotechnology Real Estate .Net Conference 105

GeekWire

AUGUST 26, 2020

The Seattle biotech filed initial IPO paperwork Wednesday, a surprising move that would give the company additional capital to develop its therapies for brain diseases. Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. In its IPO paperwork, Athira reports a net loss of $5.2

Biotechnology 140

Biotechnology .Net Healthcare Development 140

CTOvision

FEBRUARY 10, 2016

The technology was developed under DARPA’s Reliable Neural-Interface Technology (RE-NET) program , and offers new potential for safely expanding the use of brain-machine interfaces (BMIs) to treat physical disabilities and neurological disorders.

.Net 150

.Net Biotechnology Study Research 150

GeekWire

JULY 22, 2021

Absci, which is developing technologies to accelerate drug discovery, is riding a wave of biotech IPOs. Absci joins several other Washington state biotechs that have gone public this year, including Sana Biotechnology , Impel Neuropharma , and Nautilus Biotechnology, which went public via a SPAC merger. Net losses were $14.4

Company 127

Company Biotechnology .Net Engineering 127

GeekWire

SEPTEMBER 17, 2020

Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. Formerly known as M3 Biotechnology, the company is led by Dr. Leen Kawas , a 35-year-old CEO who will be the first woman to guide a company to an initial public offering in Washington state in more than two decades.

Biotechnology 108

Biotechnology .Net Company Report 108

GeekWire

OCTOBER 9, 2024

Phase Genomics has developed technology for sequencing DNA from wide-ranging and tricky to study organisms. Other former positions include leadership roles at the Gates Foundation and directing the global drug development program at PATH. Susan Wyrick of Sana Biotechnology.

Biotechnology 111

Biotechnology Microsoft Dell Education 111

GeekWire

DECEMBER 27, 2022

He’s now CEO of Nautilus Biotechnology, and he’s not taking any big chances in the current economic downturn. “As a development stage company, we’re doing everything we can to strike the right balance between accelerating the development of our platform while seeking to extend our cash runway,” said Patel.

Industry 117

Industry Biotechnology CTO Company 117

Trends in the Living Networks

MARCH 23, 2011

Their joint work on a process for cloning genes in microorganisms resulted in three patents that formed the foundation of the nascent biotechnology industry. Do you need to come up with startlingly new and different ideas, or do you have to develop the seed of an idea into something useful and workable?

Open Source 138

Open Source Film Development Network 138

GeekWire

SEPTEMBER 18, 2020

Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. ” Athira, previously known as M3 Biotechnology, plans to double the size of its 20-person team as it relocates into a larger facility in Bothell, Wash. In its IPO paperwork, Athira reported a net loss of $5.2

Biotechnology 114

Biotechnology Research Company .Net 114

GeekWire

JUNE 9, 2021

Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology is emerging as Seattle’s newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biomedical research and transform drug development.

Biotechnology 129

Biotechnology Analysis Research Engineering 129

GeekWire

FEBRUARY 8, 2021

Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC. Nautilus Photo). It values the company at $900 million.

Biotechnology 145

Biotechnology .Net Groups Company 145

Trends in the Living Networks

AUGUST 11, 2022

She has worked on projects about diverse issues such as water security, the future of energy, the future of youth, intelligent buildings, the development of cities over the next few decades, and planning for Egypt in 2030. Chung developed the curriculum and conducted training for the government’s in-house futures course, Futurecraft.

Study 148

Study Research Trends Education 148